In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

For decades, immunologists have explored CAR-T cell therapy as an effective tool to fight blood cancer. Increasingly, CAR-T cells are being explored as a potential silver bullet for treating ...

Universal solid tumor therapy with CD5-deleted, DSG2-directed CAR-T cells. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators from Baylor College of Medicine, ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

Chimeric antigen receptor (CAR) T cell therapy, a type of immunotherapy that leverages the immune system to combat diseases, is a powerful treatment option for certain cancers. The treatment relies on ...